defiteli进入医保了吗？

The recommended dose of defibrotide (Defibrotide) for adult and pediatric patients is 6.25 mg/kg given every 6 hours as a 2-hour intravenous infusion. The dose should be based on the patient's baseline weight, which is defined as the patient's weight before the HSCT preparation protocol. Defiteli is given for a minimum total of 21 days. If signs and symptoms of hepatic veno-occlusive disease (HVOD) do not resolve after 21 days, continue defiteli until resolution of HVOD or until a maximum of 60 days.

Defiteli is currently recognized as the most promising new drug for the treatment of hepatic veno-occlusive disease (HVOD) after hematopoietic stem cell transplantation (HSCT). Based on its anticoagulant, fibrinolytic promotion, anti-inflammatory and other effects.

Is defiteli covered by medical insurance? Defiteli has been approved for sale by the European Union in 2013 and by the US FDA in 2016. However, it has not yet been launched in my country, so it is naturally not included in medical insurance. Patients need to purchase defiteli at the original international price.

Richardson et al first explored the application of defiteli in the treatment of HVOD after HSCT. This study included 19 patients with sHVOD. The dose of defiteli is 5~60mg/kg per day, intravenous infusion, and the median use time is 15d (2-61d). The results showed that 42% of patients achieved complete remission (CR), and the overall survival (os) rate 100 days after transplantation reached 32%, and patients could tolerate defibrination well. Since then, multiple clinical trials have confirmed the effectiveness of defiteli in the treatment of HVOD.

Defiteli () is not yet on the market in my country and cannot be reimbursed by medical insurance. It is also inconvenient for patients to purchase this drug. If you need to purchase defiteli, you can consult your medical companion for specific information.